Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | I195* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TP53 I195* results in a premature truncation of the Tp53 protein at amino acid 195 of 393 (UniProt.org). I195* has not been biochemically characterized however, due to the effects of truncation mutations downstream of I195 (PMID: 31081129, PMID: 34045312), is predicted to lead to a loss of Tp53 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon6 TP53 I195* TP53 mutant TP53 inact mut TP53 I195* |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674946_7674948delATCinsTAA |
cDNA | c.583_585delATCinsTAA |
Protein | p.I195* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001407264.1 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674946_7674948delGATinsTTA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7674946_7674948delGATinsTTA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674946_7674948delGATinsTTA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674946_7674948delGATinsTTA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674946_7674948delATCinsTAA | c.583_585delATCinsTAA | p.I195* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 I195* TP53 R248Q | ovarian carcinoma | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848). | 26748848 |